Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 67
Filtrar
1.
ACS Appl Mater Interfaces ; 12(41): 45830-45837, 2020 Oct 14.
Artigo em Inglês | MEDLINE | ID: mdl-32936615

RESUMO

Herein, we report a novel strategy to enhance the antisense activity and the pharmacokinetics of therapeutic oligonucleotides. Through the DNA hybridization chain reaction, DNA hairpins modified with poly(ethylene glycol) (PEG) form a bottlebrush architecture consisting of a double-stranded DNA backbone, PEG side chains, and antisense overhangs. The assembled structure exhibits high PEG density on the surface, which suppresses unwanted interactions between the DNA and proteins (e.g., enzymatic degradation) while allowing the antisense overhangs to hybridize with the mRNA target and thereby deplete target protein expression. We show that these PEGylated bottlebrushes targeting oncogenic KRAS can achieve much higher antisense efficacy compared with unassembled hairpins with or without PEGylation and can inhibit the proliferation of lung cancer cells bearing the G12C mutant KRAS gene. Meanwhile, these structures exhibit elevated blood retention times in vivo due to the biological stealth properties of PEG and the high molecular weight of the overall assembly. Collectively, this self-assembly approach bears the characteristics of a simple, safe, yet highly translatable strategy to improve the biopharmaceutical properties of therapeutic oligonucleotides.


Assuntos
DNA/química , Oligonucleotídeos Antissenso/farmacocinética , Polietilenoglicóis/química , Animais , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , DNA/sangue , Camundongos , Camundongos Endogâmicos C57BL , Estrutura Molecular , Oligonucleotídeos Antissenso/sangue , Oligonucleotídeos Antissenso/química , Distribuição Tecidual
2.
Nucleic Acid Ther ; 30(5): 265-275, 2020 10.
Artigo em Inglês | MEDLINE | ID: mdl-32833564

RESUMO

Inotersen (TEGSEDI™) is a 2'-O-(2-methoxyethyl)-modified antisense oligonucleotide, intended for treating hereditary transthyretin (TTR) amyloidosis with polyneuropathy. The potential immunogenicity (IM) response to inotersen was evaluated in chronic nonclinical safety studies and the pivotal phase 2/3 clinical study. The evaluation was designed to assess the characteristics of antidrug antibodies (ADAs) and their effects on the pharmacokinetics, pharmacodynamics, clinical efficacy, and safety in animals and humans. No immunogenic response was observed after long-term treatment with inotersen in mice. In monkeys, the incidence rate of IM to inotersen appeared to be dose dependent, with 28.6%-50.0% of animals developing ADAs after 36 weeks of treatment. This was characterized as late onset (median onset of 185 days) with low titers (median titer of 8, or 400 if minimum required dilution of 50 is included). The overall incidence rate of patients who developed ADAs was 30% after 65 weeks of treatment with median onset of 203 days and median peak titer of 300. IM had minimal effect on plasma peak (Cmax) and total exposure (i.e. area under curve, AUC) of inotersen, but showed elevated plasma trough levels in both IM-positive animals and humans. However, ADAs had no effect on tissue exposure, TTR messenger RNA, or plasma TTR levels in the long-term monkey study. Similarly, IM showed no effect on plasma TTR levels in clinical studies. Thus, ADAs antibodies were binding antibodies, but not neutralizing antibodies. Finally, no association was observed between IM and toxicity findings (eg, platelet, complement activation, and histopathology findings) in the inotersen 9-month monkey study. In humans, no difference was observed in hematology, including platelets, kidney function tests, or incidence of adverse events between IM-positive and -negative patients. Overall, IM showed no effect on toxicity or safety of inotersen evaluated in both monkeys and humans. ClinicalTrials.gov Identifier: NCT01737398.


Assuntos
Doença de Charcot-Marie-Tooth/tratamento farmacológico , Oligonucleotídeos Antissenso/administração & dosagem , Oligonucleotídeos/administração & dosagem , Oligorribonucleotídeos/administração & dosagem , Pré-Albumina/genética , Animais , Anticorpos Anti-Idiotípicos/sangue , Anticorpos Anti-Idiotípicos/imunologia , Plaquetas/imunologia , Doença de Charcot-Marie-Tooth/sangue , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/imunologia , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/patologia , Feminino , Haplorrinos , Humanos , Imunogenicidade da Vacina/genética , Imunogenicidade da Vacina/imunologia , Testes de Função Renal , Masculino , Camundongos , Oligonucleotídeos/efeitos adversos , Oligonucleotídeos Antissenso/efeitos adversos , Oligonucleotídeos Antissenso/sangue , Oligonucleotídeos Antissenso/farmacocinética , Oligorribonucleotídeos/efeitos adversos , Oligorribonucleotídeos/sangue , Oligorribonucleotídeos/farmacocinética , Pré-Albumina/antagonistas & inibidores , Pré-Albumina/imunologia
3.
Anal Chem ; 92(15): 10548-10559, 2020 08 04.
Artigo em Inglês | MEDLINE | ID: mdl-32628461

RESUMO

Quantitative bioanalysis in plasma and tissues samples is required to study the pharmacokinetic and pharmacodynamic properties of antisense oligonucleotides (ASOs). To overcome intrinsic drawbacks in specificity, sensitivity, and throughput of traditional ligand-binding assay (LBA) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods, an alternative bioanalytical method was developed by combining oligonucleotide hybridization and LC-MS/MS technologies. Target ASOs were extracted from biological samples by hybridization with biotinylated sense-strand oligonucleotides coupled to streptavidin magnetic beads. Using ion-pairing chromatography and tandem mass spectrometry, this method demonstrated high sensitivity (0.5 ng/mL using 100 µL of plasma), high specificity, wide linear range, complete automation, and generic applications in tests with multiple ASOs. The typical challenge of sensitivity drop in traditional ion-pairing LC-MS/MS was for the first time overcome by the introduction of a ternary pump system. Due to the high specificity, quantitation in various biological matrixes was achieved using calibration standards in plasma, largely improving efficiency and consistency. Another major advantage was the capability of simultaneous quantitation of ASO metabolites. The hybridization LC-MS/MS was considered an improved alternative for quantitation of ASOs and metabolites in plasma and tissue samples, showing a great potential to replace traditional LBA and LC-MS/MS methods.


Assuntos
Cromatografia Líquida/métodos , Oligonucleotídeos Antissenso/sangue , Oligonucleotídeos Antissenso/química , Animais , Feminino , Infusões Intraventriculares , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Oligonucleotídeos Antissenso/administração & dosagem , Oligonucleotídeos Antissenso/farmacocinética , Sensibilidade e Especificidade , Espectrometria de Massas em Tandem
4.
J Chromatogr Sci ; 58(4): 383-387, 2020 Apr 23.
Artigo em Inglês | MEDLINE | ID: mdl-32043121

RESUMO

The presented studies aimed to develop a new and simple extraction method based on hydrophilic interaction for antisense oligonucleotides with different modifications. For this purpose, solid-phase extraction cartridges with unmodified silica were used. All extraction steps were performed by utilizing water, acetonitrile, acetone or their mixtures. The results obtained show that a high content (95%) of organic solvent, used during sample loading, is critical to achieve a successful extraction, while elution with pure water allows effective oligonucleotides desorption. The recovery values were greater than 90% in the case of unmodified DNA, phosphorothioate, 2'-O-(2-methoxyethyl) and 2'-O-methyl oligonucleotides. For the mixture of phosphorothioate oligonucleotide and its two synthetic metabolites, the recovery values for the standard solutions were in the range of 70-75%, while for spiked human plasma, 45-50%. The developed method is simple, may be performed in a short time and requires simple solvents like water or acetonitrile/acetone, thus showing promise as an alternative to chaotropic salt-based or ion pair-based SPE methods.


Assuntos
Oligonucleotídeos Antissenso/química , Oligonucleotídeos Antissenso/isolamento & purificação , Extração em Fase Sólida/métodos , Acetona/química , Acetonitrilas/química , Humanos , Interações Hidrofóbicas e Hidrofílicas , Oligonucleotídeos Antissenso/sangue , Oligonucleotídeos Fosforotioatos/sangue , Oligonucleotídeos Fosforotioatos/química , Oligonucleotídeos Fosforotioatos/isolamento & purificação , Dióxido de Silício/química , Extração em Fase Sólida/instrumentação , Solventes/química
6.
Regul Toxicol Pharmacol ; 103: 130-139, 2019 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-30682377

RESUMO

Midkine antisense oligonucleotide (MK-ASODN) nanoliposomes have previously been shown to have inhibitory activity against hepatocellular carcinoma growth. Herein we report the 4-week sub-chronic toxicity of MK-ASODN nanoliposomes in SD rats. The adverse effects included loss of body weight gain and food consumption, peri-rhinal bleeding, piloerection, peri-anal filth, and kidney, liver, spleen, thymus, lung, and injection site lesions at high doses. Macroscopic changes were observed in the kidneys of the high-dose group, accompanied by a variation in urine protein and white blood cells, blood urea nitrogen, and serum creatinine. The increased spleen and liver coefficient, and the variation in circulating white blood cells, lymphocytes, and eosinophils in the high-dose group demonstrated that inflammation was caused by MK-ASODN nanoliposomes and was consistent with the macroscopic changes in the spleen and liver. The main necropsy findings of the animals that died were macroscopic changes in the lung. No severe toxic effects or mortalities occurred in the low- and medium-dose groups. However, a No Adverse Effect Level (NOAEL) was not identified since there were changes in organs deemed to be adverse at all dose levels. Thus, the maximum tolerated dose of MK-ASODN nanoliposomes for rats was considered to be 6 mg/kg/day.


Assuntos
Midkina/toxicidade , Nanopartículas/toxicidade , Oligonucleotídeos Antissenso/toxicidade , Animais , Relação Dose-Resposta a Droga , Feminino , Injeções Intravenosas , Lipossomos/administração & dosagem , Lipossomos/toxicidade , Fígado/efeitos dos fármacos , Masculino , Midkina/administração & dosagem , Midkina/sangue , Nanopartículas/administração & dosagem , Oligonucleotídeos Antissenso/administração & dosagem , Oligonucleotídeos Antissenso/sangue , Ratos , Ratos Sprague-Dawley , Baço/efeitos dos fármacos
7.
Nucleic Acid Ther ; 29(1): 16-32, 2019 02.
Artigo em Inglês | MEDLINE | ID: mdl-30570431

RESUMO

Advances in medicinal chemistry have produced new chemical classes of antisense oligonucleotides (ASOs) with enhanced therapeutic properties. Conjugation of the triantennary N-acetylgalactosamine (GalNAc3) moiety to the extensively characterized phosphorothioate (PS)-modified 2'-O-methoxyethyl (2'MOE) ASO exemplifies such an advance. This structure-activity optimized moiety effects receptor-mediated uptake of the ASO prodrug through the asialoglycoprotein receptor 1 to support selective targeting of RNAs expressed by hepatocytes. In this study we report the integrated assessment of data available from randomized placebo-controlled dose-ranging studies of this chemical class of ASOs administered systemically to healthy human volunteers. First, we compare the pharmacokinetic and pharmacodynamic profiles of a subset of the GalNAc3-conjugated PS-modified 2'MOE ASOs to the parent PS-modified 2'MOE ASOs for which plasma analytes are available. We then evaluate the safety profile of the full set of GalNAc3-conjugated PS-modified 2'MOE ASO conjugates by the incidence of signals in standardized laboratory tests and by the mean laboratory test results as a function of dose level over time. With hepatocyte targeted delivery, the ED50 for the GalNAc3-conjugated PS-modified 2'MOE ASO subset ranges from 4 to 10 mg/week, up to 30-fold more potent than the parent PS-modified 2'MOE ASO. No GalNAc3-conjugated PS-modified 2'MOE ASO class effects were identified from the assessment of the integrated laboratory test data across all doses tested with either single or multidose regimens. The increase in potency supports an increase in the safety margin for this new chemical class of ASOs now under broad investigation in the clinic. Although the total exposure is limited in the initial phase 1 trials, ongoing and future investigations in patient populations will support evaluation of the effects of long-term exposure.


Assuntos
Acetilgalactosamina/administração & dosagem , Receptor de Asialoglicoproteína/genética , Oligonucleotídeos Antissenso/administração & dosagem , Oligonucleotídeos Fosforotioatos/administração & dosagem , Acetilgalactosamina/sangue , Acetilgalactosamina/farmacocinética , Receptor de Asialoglicoproteína/sangue , Biomarcadores Farmacológicos/sangue , Relação Dose-Resposta a Droga , Feminino , Voluntários Saudáveis , Hepatócitos/efeitos dos fármacos , Humanos , Masculino , Pessoa de Meia-Idade , Oligonucleotídeos Antissenso/sangue , Oligonucleotídeos Antissenso/farmacocinética , Oligonucleotídeos Fosforotioatos/sangue , Oligonucleotídeos Fosforotioatos/farmacocinética , RNA/antagonistas & inibidores , RNA/sangue , RNA/genética , Relação Estrutura-Atividade
8.
Nucleic Acid Ther ; 28(6): 319-325, 2018 12.
Artigo em Inglês | MEDLINE | ID: mdl-30328765

RESUMO

Knowledge of the kinetics of the active drug in biophase, that is, at the effect site, is fundamental to select dose and to reason about safety. Unfortunately, the kinetics is cumbersome to measure in vivo. We describe how dose-response-time (DRT) analysis estimates the biophase and the target-response half-lives from data of the circulating protein of the encoded messenger RNA for seven antisense oligonucleotides (ASOs) and four small interfering RNA (siRNA) drugs. The biophase half-lives were estimated with acceptable precision (relative standard error <26%). For ASOs, the estimates were similar to, or slightly longer than, the reported terminal plasma half-lives. Terminal plasma half-life was reported for only one siRNA, precluding any general comparison. The estimated half-lives of response were 0.5-12 days cross drugs and shorter than the biophase half-lives. We recommend DRT analysis when limited plasma pharmacokinetic data are available, or when the biophase half-life differs from the terminal plasma half-life.


Assuntos
Biomarcadores Farmacológicos/sangue , Oligonucleotídeos Antissenso/farmacocinética , RNA Mensageiro/sangue , RNA Interferente Pequeno/farmacocinética , Relação Dose-Resposta a Droga , Feminino , Meia-Vida , Humanos , Cinética , Masculino , Oligonucleotídeos Antissenso/sangue , Oligonucleotídeos Antissenso/uso terapêutico , RNA Mensageiro/genética , RNA Interferente Pequeno/sangue , RNA Interferente Pequeno/uso terapêutico
9.
Nucleic Acid Ther ; 27(5): 285-294, 2017 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-28799823

RESUMO

The potential of QT prolongation of ten 2'-O-methoxyethyl-modified (2'-MOE) antisense oligonucleotides (ASOs) was evaluated retrospectively via exposure/response (ER) analysis using data from Phase 1 clinical studies in healthy subjects. All Phase 1 studies were double-blind, placebo-controlled, single and multiple ascending dose studies designed to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of the ASOs in healthy subjects. The active doses in these studies ranged from 50 to 450 mg administered by subcutaneous (SC) injection in single and multiple ascending dose cohorts. Two of the ten studies also included 2-h intravenous (IV) infusions up to 600 mg. Electrocardiogram (ECG) measurements were performed at baseline and selected time points (including Tmax). The correlation between QTcF intervals corrected for baseline (ΔQTcF) and the mean time-matched placebo (ΔΔQTcF) with PK plasma exposure when available was evaluated using a linear mixed-effects approach. There was no evidence for QTc prolongation associated with increasing plasma concentrations in healthy subjects, including exposures with treatment up to 450 mg administered SC or 600 mg by IV infusions, and concentrations that are 4-20 times the Cmax of the therapeutic dose, as assessed by both ΔQTcF and ΔΔQTcF. The ER analysis of the relationship between drug plasma concentration and ΔΔQTcF showed that the slope of the regression line was close to zero, and the upper bound of the 90% confidence interval at twice the mean observed (or predicted) Cmax (2 × Cmax) of the clinical therapeutic dose (ie, the highest clinically relevant plasma concentration) was well below 10 ms for all 10 compounds evaluated. Therefore, no concentration-dependent effect on QT prolongation was observed for any one of the ten 2'-MOE ASOs evaluated in Phase 1 studies. These results confirmed that 2'-MOE ASOs, as a chemical class, do not cause QT prolongation at clinically relevant dose levels.


Assuntos
Eletrocardiografia , Oligonucleotídeos Antissenso/administração & dosagem , Oligonucleotídeos Antissenso/farmacocinética , Adulto , Estudos de Coortes , Estudos Cross-Over , Relação Dose-Resposta a Droga , Método Duplo-Cego , Feminino , Voluntários Saudáveis , Humanos , Masculino , Oligonucleotídeos Antissenso/sangue , Estudos Retrospectivos
10.
Bioconjug Chem ; 28(3): 768-774, 2017 03 15.
Artigo em Inglês | MEDLINE | ID: mdl-28292178

RESUMO

Specific target binding and stability in diverse biological media is of crucial importance for applications of synthetic oligonucleotides as diagnostic and therapeutic tools. So far, these issues have been addressed by chemical modification of oligonucleotides and by conjugation with a peptide, most often at the terminal position of the oligonucleotide. Herein, we for the first time systematically investigate the influence of internally attached short peptides on the properties of antisense oligonucleotides. We report the synthesis and internal double labeling of 21-mer oligonucleotides that target the BRAF V600E oncogene, with a library of rationally designed peptides employing CuAAC "click" chemistry. The peptide sequence has an influence on the specificity and affinity of target DNA/RNA binding. We also investigated the impact of locked nucleic acids (LNAs) on the latter. Lysine residues improve binding of POCs to target DNA and RNA, whereas the distance to lysine correlates exclusively with a decrease in binding of mismatched RNA targets. Glycine and tyrosine residues affect target binding as well. Importantly, the resistance of POCs to enzymatic degradation is dramatically improved by the internal attachment of peptides but not by LNA alone. Independently of the peptide sequence, the conjugates are stable for up to 24 h in 90% human serum and duplexes of POCs with complementary DNA for up to 160 h in 90% human serum. Such excellent stability has not been previously reported for DNA and makes internally labeled POCs an exciting object of study, i.e., showing high target specificity and simultaneous stability in biological media.


Assuntos
Oligonucleotídeos Antissenso/química , Peptídeos/química , Sequência de Aminoácidos , Sequência de Bases , Química Click , DNA/genética , DNA/metabolismo , Humanos , Oligonucleotídeos/sangue , Oligonucleotídeos/química , Oligonucleotídeos/genética , Oligonucleotídeos/metabolismo , Oligonucleotídeos Antissenso/sangue , Oligonucleotídeos Antissenso/genética , Oligonucleotídeos Antissenso/metabolismo , Biblioteca de Peptídeos , Peptídeos/sangue , Peptídeos/metabolismo , Proteínas Proto-Oncogênicas B-raf/genética , RNA/genética , RNA/metabolismo
11.
Br J Clin Pharmacol ; 83(9): 1932-1943, 2017 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-28294391

RESUMO

AIMS: Custirsen (OGX-011/TV-1011), a second-generation antisense oligonucleotide that reduces clusterin production, is under investigation with chemotherapy in prostate and lung cancer. This meta-analysis evaluated the population pharmacokinetics (PK) of custirsen in cancer patients and healthy subjects. METHODS: The population PK analysis used custirsen plasma concentrations from five Phase 1 studies, one Phase 1/2 study, and one Phase 3 study in two stages. Cancer patients received multiple doses of custirsen (40-640 mg intravenously over 120 min) with chemotherapy; healthy subjects received single or multiple doses (320-640 mg). An interim population PK model was developed using a nonlinear mixed-effect approach incorporating data from four Phase 1 or 1/2 studies, followed by model refinement and inclusion of two Phase 1 and one Phase 3 studies. RESULTS: The final model was developed with 5588 concentrations from 631 subjects with doses of 160-640 mg. Custirsen PK was adequately described by a three-compartment model with first-order elimination. For a representative 66-year-old individual with body weight 82 kg and serum creatinine level 0.933 mg dl-1 , the estimated typical (95% CI) parameter values were clearance (CL) = 2.36 (2.30-2.42) l h-1 , central volume of distribution (V1 ) = 6.08 (5.93-6.23) l, peripheral volume of distribution (V2 ) = 1.13 (1.01-1.25) l, volume of the second peripheral compartment (V3 ) = 15.8 (14.6-17.0) l, inter-compartmental clearance Q2 = 0.0755 (0.0689-0.0821) l h-1 , and Q3 = 0.0573 (0.0532-0.0614) l h-1 . Age, weight and serum creatinine were predictors of CL; age was a predictor of Q3 . CONCLUSION: A population PK model for custirsen was successfully developed in cancer patients and healthy subjects, including covariates contributing to variability in custirsen PK.


Assuntos
Ensaios Clínicos como Assunto/estatística & dados numéricos , Tionucleotídeos/farmacocinética , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Relação Dose-Resposta a Droga , Feminino , Voluntários Saudáveis , Humanos , Infusões Intravenosas , Masculino , Pessoa de Meia-Idade , Neoplasias/sangue , Dinâmica não Linear , Oligonucleotídeos Antissenso/administração & dosagem , Oligonucleotídeos Antissenso/sangue , Oligonucleotídeos Antissenso/farmacocinética , Tionucleotídeos/administração & dosagem , Tionucleotídeos/sangue , Adulto Jovem
12.
J Pharmacokinet Pharmacodyn ; 42(1): 67-77, 2015 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-25376372

RESUMO

Second-generation antisense oligonucleotides (ASOs) demonstrate excellent biological stability and in vitro/in vivo potency, and thus are considered to be attractive candidates for drugs to treat various diseases. A pharmacokinetic-pharmacodynamic (PK-PD) model of ASOs is desired for the design of appropriate PK and pharmacological studies. The objective of this study was to develop a PK-PD model to accurately simulate hepatic ASO concentration and its efficacy from plasma ASO concentration. After single subcutaneous administration of an ASO targeting hepatic apolipoprotein B (Apo-B) mRNA to mice, the ASO was absorbed rapidly and showed biphasic decline with time from the plasma and liver (t1/2: 1-3 and 81-183 h, Tmax: 0.25-0.50 and 4-8 h). After administration, hepatic Apo-B mRNA and plasma total cholesterol began decreasing at 4-8 and 8-24 h, and their Tmax values were observed at 24-72 and 72 h. To develop the PK-PD model based on the mechanisms of ASOs, we described the plasma and hepatic ASO concentration with linear two-compartment models. In addition, we inserted two indirect response models for mRNA and plasma total cholesterol. Model predictions from plasma ASO concentration gave excellent fits to the observed values of hepatic ASO concentration, Apo-B mRNA and plasma total cholesterol after single or multiple subcutaneous administrations. Our PK-PD model could accurately predict hepatic ASO concentrations and their efficacies from plasma ASO concentrations. This PK-PD model could be a useful tool for suggesting PK and pharmacological study protocols for various liver-targeted second-generation ASOs.


Assuntos
Apolipoproteínas B/antagonistas & inibidores , Colesterol/sangue , Fígado , Modelos Biológicos , Oligonucleotídeos Antissenso/farmacologia , Oligonucleotídeos Antissenso/farmacocinética , RNA Mensageiro/antagonistas & inibidores , Animais , Apolipoproteína B-100 , Simulação por Computador , Feminino , Fígado/efeitos dos fármacos , Fígado/metabolismo , Camundongos Endogâmicos C57BL , Oligonucleotídeos Antissenso/sangue , Fatores de Tempo
13.
Anal Bioanal Chem ; 406(28): 7127-36, 2014 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24939137

RESUMO

Ultra high-performance [corrected] liquid chromatography has been used for the separation and analysis of unmodified and modified antisense oligonucleotides. For this reason, we tested various columns of low particle sizes in our analysis of unmodified and phosphorothioate oligonucleotides. The influence of both the type and concentration of ion-pair reagent on the retention of the studied biomolecules was tested. The developed methods were used for separation of unmodified oligonucleotides and to determine antisense oligonucleotides in human serum samples. The results proved that octadecyl and phenyl columns are the most selective in the resolution of oligonucleotides which differ in the position of single nucleotides in the sequence. The phenyl column was selected and applied for the analysis of phosphorothioate oligonucleotides in serum samples. The calibration plots showed good linearity within the test concentration ranges. The intra-day CV of the calibration curve slopes was in the range of 1.6 to 4.2 %. The limits of detection (LODs) were in the range of 0.11-0.16 µg mL(-1), while the limit of quantification (LOQ) values were between 0.35 and 0.51 µg mL(-1).


Assuntos
Cromatografia Líquida de Alta Pressão/métodos , Oligonucleotídeos Antissenso/sangue , Oligonucleotídeos Antissenso/química , Oligonucleotídeos Fosforotioatos/sangue , Calibragem , Humanos , Limite de Detecção
14.
Inhal Toxicol ; 26(8): 452-63, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-24932560

RESUMO

Antisense oligonucleotides (ASOs) bind and facilitate degradation of RNA and inhibit protein expression in pathways not easily targeted with small molecules or antibodies. Interleukin (IL)-4 and IL-13 potentiate signaling through the shared IL-4 receptor-α (IL-4Rα) subunit of their receptors. ASO targeting of IL-4Rα mRNA in a mouse model of asthma led to attenuation of airway hyperactivity, demonstrating potential benefit in asthma patients. This study focused on tolerability of inhaled IL-4Rα-targeting ASOs. Toxicity studies were performed with mouse- (ISIS 23189) and human-specific (ISIS 369645) sequences administered by inhalation. Four week (monkey) or 13 week (mouse) repeat doses at levels of up to 15 mg/kg/exposure (exp) and 50 mg/kg/exp, respectively, demonstrated dose-dependent effects limited to increases in macrophage size and number in lung and tracheobronchial lymph nodes. The changes were largely non-specific, reflecting adaptive responses that occur during active exposure and deposition of ASO and other material in the lung. Reversibility was observed at a rate consistent with the kinetics of tissue clearance of ASO. Systemic bioavailability was minimal, and no systemic toxicity was observed at exposure levels appreciably above pharmacological doses and doses proposed for clinical trials.


Assuntos
Pulmão/efeitos dos fármacos , Oligonucleotídeos Antissenso/toxicidade , Oligonucleotídeos/toxicidade , Receptores de Superfície Celular/genética , Animais , Feminino , Pulmão/metabolismo , Pulmão/patologia , Pulmão/fisiologia , Macaca , Masculino , Camundongos , Oligonucleotídeos/sangue , Oligonucleotídeos/farmacocinética , Oligonucleotídeos Antissenso/sangue , Oligonucleotídeos Antissenso/farmacocinética , RNA Mensageiro/metabolismo
15.
Invest New Drugs ; 31(4): 1023-34, 2013 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-23397500

RESUMO

Survivin is expressed in tumor cells, including acute myeloid leukemia (AML), regulates mitosis, and prevents tumor cell death. The antisense oligonucleotide sodium LY2181308 (LY2181308) inhibits survivin expression and may cause cell cycle arrest and restore apoptosis in AML. In this study, the safety, pharmacokinetics, and pharmacodynamics/efficacy of LY2181308 was examined in AML patients, first in a cohort with monotherapy (n = 8) and then post-amendment in a cohort with the combination of cytarabine and idarubicin treatment (n = 16). LY2181308 was administered with a loading dosage of three consecutive daily infusions of 750 mg followed by weekly intravenous (IV) maintenance doses of 750 mg. Cytarabine 1.5 g/m(2) was administered as a 4-hour IV infusion on Days 3, 4, and 5 of Cycle 1, and idarubicin 12 mg/m(2) was administered as a 30-minute IV infusion on Days 3, 4, and 5 of Cycle 1. Cytarabine and idarubicin were administered on Days 1, 2, and 3 of each subsequent 28-day cycle. Reduction of survivin was evaluated in peripheral blasts and bone marrow. Single-agent LY2181308 was well tolerated and survivin was reduced only in patients with a high survivin expression. In combination with chemotherapy, 4/16 patients had complete responses, 1/16 patients had incomplete responses, and 4/16 patients had cytoreduction. Nine patients died on study: 6 (monotherapy), 3 (combination). LY2181308 alone is well tolerated in patients with AML. In combination with cytarabine and idarubicin, LY2181308 does not appear to cause additional toxicity, and has shown some clinical benefit needing confirmation in future clinical trials.


Assuntos
Antineoplásicos/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Citarabina/uso terapêutico , Idarubicina/uso terapêutico , Leucemia Mieloide Aguda/tratamento farmacológico , Oligonucleotídeos/efeitos adversos , Oligonucleotídeos/farmacocinética , Antineoplásicos/efeitos adversos , Antineoplásicos/sangue , Antineoplásicos/farmacocinética , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/sangue , Protocolos de Quimioterapia Combinada Antineoplásica/farmacocinética , Citarabina/efeitos adversos , Citarabina/sangue , Citarabina/farmacocinética , Demografia , Feminino , Humanos , Idarubicina/efeitos adversos , Idarubicina/sangue , Idarubicina/farmacocinética , Proteínas Inibidoras de Apoptose/metabolismo , Leucemia Mieloide Aguda/sangue , Masculino , Pessoa de Meia-Idade , Oligonucleotídeos/sangue , Oligonucleotídeos/uso terapêutico , Oligonucleotídeos Antissenso/efeitos adversos , Oligonucleotídeos Antissenso/sangue , Oligonucleotídeos Antissenso/farmacocinética , Oligonucleotídeos Antissenso/uso terapêutico , Recidiva , Survivina , Resultado do Tratamento
16.
J Pharm Biomed Anal ; 71: 228-32, 2012 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-22944355

RESUMO

TP53 encodes for tumor protein p53. The suppression of p53 protein results in interruption of DNA repair mechanisms in dividing malignant cells thereby increasing the DNA damage and activating p53-independent mechanisms of apoptosis. This ultimately may translate into enhanced cytotoxic effects of standard chemotherapy. Based on this rationale, Cenersen, a phosphorothioate oligonucleotide antisense to p53-mRNA was synthesized and tested in clinical trials for patients with acute myeloid leukemia (AML). An important component of Cenersen clinical development is to develop a sensitive and specific method to quantify plasma and intracellular levels of Cenersen in different biologic matrices in order to determine tissue and intracellular distribution of the parent compound and its metabolites. Ultimately, this will allow us to determine pharmacokinetic and pharmacodynamic relationship for dose-effect correlation and design effective regimen to be rapidly translate into the clinic. An ELISA-based assay was adapted for assay development and validation of Cenersen in mouse plasma and cell lysate. Cellular uptake of Cenersen was studied in MV4-11 and KASUMI-1 AML cell lines. Real-time RT-PCR was used to measure P53-mRNA expression changes in treated cells. The assay had a limit of quantification of 35pmol/L in mouse plasma. Within-day and between-day precision of <15% and accuracy nearly 100% were observed in a linear range of 10-2000pmol/L (R(2)=0.99) in AML cell lysate. The selectivity of this assay examined as cross-reactivity with its 3'N-1, 3'N-2-metabolites, was 16.8% and 0.4%, respectively, and with its mismatch and the scramble oligonucleotides was 0.06% and 0.4%, respectively. Cenersen was stable in mouse plasma up to 8h at 37°C. When exposed to 0.1-1µmol/L Cenersen, MV4-11 and KASUMI-1 cells showed intracellular concentration in the range of 9.97-45.34nmol/mg protein and 0.1-2.1nmol/mg protein, respectively. Successful downregulation of p53-mRNA expression was observed in Cenersen treated cells. This ELISA-based assay was applicable to plasma and intracellular concentration measurement of Cenersen. Assessment of achievable concentration of Cenersen in different biologic matrices will be useful to elucidate the biological and clinical activity of this promising drug and define its recommended dose in future clinical trials.


Assuntos
Leucemia Mieloide Aguda/sangue , Oligonucleotídeos Antissenso/sangue , Oligonucleotídeos Antissenso/farmacocinética , Oligonucleotídeos/sangue , Oligonucleotídeos/farmacocinética , Proteína Supressora de Tumor p53/genética , Animais , Linhagem Celular Tumoral , Ensaio de Imunoadsorção Enzimática/métodos , Humanos , Células K562 , Leucemia Mieloide Aguda/genética , Leucemia Mieloide Aguda/metabolismo , Camundongos , Oligonucleotídeos Antissenso/genética , RNA Mensageiro/genética , Sensibilidade e Especificidade , Distribuição Tecidual , Proteína Supressora de Tumor p53/metabolismo
17.
J Org Chem ; 76(11): 4408-31, 2011 Jun 03.
Artigo em Inglês | MEDLINE | ID: mdl-21500818

RESUMO

Using the intramolecular 5-exo-5-hexenyl radical as a key cyclization step, we previously reported an unambiguous synthesis of carba-LNA thymine (cLNA-T), which we subsequently incorporated in antisense oligonucleotides (AON) and investigated their biochemical properties [J. Am. Chem. Soc.2007, 129 (26), 8362-8379]. These cLNA-T incorporated oligos showed specific RNA affinity of +3.5-5 °C/modification for AON:RNA heteroduplexes, which is comparable to what is found for those of LNAs (Locked Nucleic Acids). These modified oligos however showed significantly enhanced nuclease stability (ca. 100 times more) in the blood serum compared to those of the LNA modified counterparts without compromising any RNase H recruitment capability. We herein report the synthesis of 5-methylcytosine-1-yl ((Me)C), 9-adeninyl (A), and 9-guaninyl (G) derivatives of cLNA and their oligonucleotides and report their biochemical properties as potential RNA-directed inhibitors. In a series of isosequential carba-LNA modified AONs, we herein show that all the cLNA modified AONs are found to be RNA-selective, but the magnitude of RNA-selectivity of 7'-R-Me-cLNA-G (cLNA-G) (ΔT(m) = 2.9 °C/modification) and intractable isomeric mixtures of 7'-(S/R)-Me-cLNA-T (cLNA-T, ΔT(m) = 2.2 °C/modification) was found to be better than diastereomeric mixtures of 7'-(S/R)-Me-cLNA-(Me)C with trace of cENA-(Me)C (cLNA-(Me)C, ΔT(m) = 1.8 °C/modification) and 7'-R-Me-cLNA-A (cLNA-A, ΔT(m) = 0.9 °C/modification). cLNA-(Me)C modified AONs however exhibited the best nuclease stability, which is 4-, 7-, and 20-fold better, respectively, than cLNA-T, cLNA-A, and cLNA-G modified counterparts, which in turn was more than 100 times stable than that of the native. When the modification sites are appropriately chosen in the AONs, the cLNA-A, -G, and -(Me)C modified sites in the AON:RNA hybrids can be easily recognized by RNase H, and the RNA strand of the hybrid is degraded in a specific manner, which is important for the design of oligos for therapeutic purposes. The cLNA-(Me)C modified AON/RNA, however, has been found to be degraded 4 times faster than cLNA-A and G modified counterparts. By appropriately choosing the carba-LNA modification sites in AON strands, the digestion of AON:RNA can be either totally repressed or be limited to cleavage at specific sites or at a single site only (similar to that of catalytic RNAzyme or DNAzyme). Considering all physico- and biochemical aspects of cLNA modified oligos, the work suggests that the cLNA modified antisense oligos have the potential of being a promising therapeutic candidate due to their (i) higher nucleobase-specific RNA affinity and RNA selectivity, (ii) greatly improved nuclease stability, and (iii) efficient RNase H recruitment capability, which can induce target RNA cleavage in a very specific manner at multiple or at a single site, in a designed manner.


Assuntos
Exonucleases/metabolismo , Oligonucleotídeos Antissenso/química , Oligonucleotídeos Antissenso/metabolismo , Oligonucleotídeos/química , RNA/metabolismo , Ribonuclease H/metabolismo , Sequência de Bases , Ciclização , Estabilidade Enzimática , Escherichia coli/enzimologia , Humanos , Modelos Moleculares , Conformação Molecular , Desnaturação de Ácido Nucleico , Hibridização de Ácido Nucleico , Oligonucleotídeos Antissenso/sangue , Oligonucleotídeos Antissenso/genética , Compostos Organofosforados/química , RNA/química , RNA/genética , Especificidade por Substrato , Termodinâmica , Temperatura de Transição
18.
Yao Xue Xue Bao ; 46(11): 1370-3, 2011 Nov.
Artigo em Chinês | MEDLINE | ID: mdl-22260032

RESUMO

To study the pharmacokinetics of cantide, an antisense oligonucleotide, and its metabolites after iv gtt administration in rhesus monkeys, a dual solid phase extraction pretreatment method coupling with non-gel sieving capillary electrophoresis analysis method was used for determination of cantide and its metabolites in plasma and their pharmacokinetic parameters were calculated. The pharmacokinetic behavior of cantide and its metabolites (M1 and M2) after iv gtt administration (8, 16 and 24 mg kg(-1)) in rhesus monkeys were investigated. After iv gtt administration of cantide to rhesus monkeys, cantide in plasma was eliminated rapidly and the terminal elimination half-life (t1/2) was 57.91-77.97 min, the correlation coefficients (r) to the dose of Cmax AUC(o-inf) and AUC(0-t) of the prototype was 0.9918, 0.9568 and 0.9773, respectively. The metabolites of cantide reached the Cmax following cantide immediately and the Cmax of metabolites were lower than that of the prototype. The CL(S) of cantide and its metabolites (M1 and M2) were 1.60-2.19, 5.92-8.58 and 6.07-8.78 mL min(-1) kg(-1), respectively. So, it is concluded that the Cmax of cantide and its metabolites increased with the dose, which is the same as their AUC(0-inf) and AUC(0-t). The CL(S) of metabolites were higher than that of the prototype. The MRT and t1/2 of metabolites in the high dose group increased obviously.


Assuntos
Oligonucleotídeos Antissenso/metabolismo , Oligonucleotídeos Antissenso/farmacocinética , Oligonucleotídeos Fosforotioatos/metabolismo , Oligonucleotídeos Fosforotioatos/farmacocinética , Animais , Área Sob a Curva , Eletroforese Capilar/métodos , Feminino , Meia-Vida , Infusões Intravenosas , Macaca mulatta , Masculino , Oligonucleotídeos Antissenso/sangue , Oligonucleotídeos Fosforotioatos/sangue , Extração em Fase Sólida
19.
Se Pu ; 28(6): 561-5, 2010 Jun.
Artigo em Chinês | MEDLINE | ID: mdl-20873576

RESUMO

A dual solid phase extraction (SPE) pretreatment coupling with non-gel sieving capillary electrophoresis (NGCE) analysis method was established for the quantitative determination of an antisense oligodeoxynucleotide, Cantide, in rhesus monkey plasma. The conditions of SPE and the NGCE analysis were optimized. Under the optimized conditions (the SPE conditions: the pH of loading buffer was 9.0; the volumes of loading and the elution solution for the anion-exchange column were 5 mL and 3 mL, respectively. The NGCE analysis conditions: loading gel time was 30 min and the separation voltage was 24 kV), the linear dynamic range of Cantide in rhesus monkeys plasma was 1.95-250 mg/L, and the correlation coefficient (r) was more than 0. 998. The limit of quantitation was 1.95 mg/L. The intra-batch accuracies ranged from 93.38% to 100.71% with the intra-batch relative standard deviation (RSD) less than 11%. The inter-batch accuracies were from 89.46% to 103.46% with the inter-batch RSD less than 9%. The stability experiment showed that the Cantide plasma sample was stable when stored at 4 degrees C for 24 h, room temperature.for 4 h, -80 degrees C for 30 days and freeze-thaw for 2 cycles. This method was finally successfully applied to pharmacokinetic study of Cantide in rhesus monkeys.


Assuntos
Eletroforese Capilar/métodos , Oligonucleotídeos Antissenso/sangue , Oligonucleotídeos Fosforotioatos/sangue , Animais , Macaca mulatta
20.
J Org Chem ; 75(18): 6122-40, 2010 Sep 17.
Artigo em Inglês | MEDLINE | ID: mdl-20738147

RESUMO

A new class of conformationally constrained nucleosides, α-L-ribo-carbocyclic LNA thymidine (α-L-carba-LNA-T, LNA is an abbreviation of locked nucleic acid) analogues and a novel "double-locked" α-L-ribo-configured tetracyclic thymidine (6,7'-methylene-bridged-α-L-carba-LNA-T) in which both the sugar puckering and glycosidic torsion are simultaneously constrained, have been synthesized through a key step involving 5-exo free-radical intramolecular cyclization. These α-L-carba-LNA analogues have been subsequently transformed to corresponding phosphoramidites and incorporated into isosequential antisense oligonucleotides (AONs), which have then been examined for the thermal denaturation of their duplexes, nuclease stability, and RNase H recruitment capabilities. Introduction of a single 6',7'-substituted α-L-carba-LNA-T modification in the AON strand of AON/RNA heteroduplex led to T(m) reduction by 2-3 °C as compared to the native heteroduplex, whereas the parent 2'-oxa-α-L-LNA-T modification at the identical position in the AON strand has been found to lead to an increase in the T(m) by 3-5 °C. This suggests that the 6' and 7' substitutions lead to much reduced thermal stability for the modified heteroduplex, especially the hydrophobic 7'-methyl on α-L-carba-LNA, which is located in the major groove of the duplex. All of the AONs incorporating 6',7'-substituted α-L-carba-LNA-T have, however, showed considerably improved nuclease stability toward 3'-exonuclease (SVPDE) and in human blood serum compared to the 2'-oxa-α-L-LNA-T incorporated AONs. The hybrid duplexes that are formed by 6',7'-substituted α-L-carba-LNA-T-modified AONs with complementary RNA have been found to recruit RNase H with higher efficiency than those of the ß-D-LNA-T or ß-D-carba-LNA-T-modified counterparts. These greatly improved nuclease resistances and efficient RNase H recruitment capabilities elevate the α-L-carba-LNA-modified nucleotides into a new class of locked nucleic acids for potential RNA targeting therapeutics.


Assuntos
Oligonucleotídeos Antissenso/síntese química , Oligonucleotídeos/síntese química , Ribonuclease H/química , Ciclização , Radicais Livres/química , Humanos , Conformação de Ácido Nucleico , Oligonucleotídeos/sangue , Oligonucleotídeos/química , Oligonucleotídeos Antissenso/sangue , Oligonucleotídeos Antissenso/química , Ribonuclease H/metabolismo , Estereoisomerismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...